UTAH MEDICAL PRODUCTS INC

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

UTMD$72.86-0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Income and Comprehensive Income

UTAH MEDICAL PRODUCTS, INC.
CONSOLIDATED STATEMENTS OF INCOME
AND COMPREHENSIVE INCOME
Years ended December 31, 2025, 2024 and 2023
(In thousands, except per share amounts)
2025 · 2024 · 2023
Sales, net (notes 1, 3, 9 and 11)		$38,520		$40,903		$50,224
Cost of goods sold		16,519		16,760		20,186
		Gross profit		22,001		24,143		30,038
Operating expense:
	Sales and marketing		2,051		1,901		1,685
	Research and development		668		813		560
	General and administrative		7,880		7,835		11,016
		Operating income		11,402		13,594		16,777
Other income (expense):
	Dividend and interest income		2,808		3,367		3,036
	Royalty income (note 12)		20		15		20
	Other, net		(120)		(174)		256
		Income before provision for income taxes		14,110		16,802		20,089
Provision for income taxes (note 7)		2,824		2,928		3,454
		Net income		$11,286		$13,874		$16,635
Earnings per common share (basic) (note 1):		$3.48		$3.96		$4.58
Earnings per common share (diluted) (note 1):		$3.48		$3.96		$4.57
Other comprehensive income (loss):
	Foreign currency translation net of taxes of $0 in all periods		$2,492		$(1,249)		$1,381
		Total comprehensive income		$13,778		$12,625		$18,016
See accompanying notes to financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.